Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1

This study has been completed.
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Lauren M. Jansson, Johns Hopkins University Identifier:
First received: September 20, 2005
Last updated: February 20, 2013
Last verified: February 2013

September 20, 2005
February 20, 2013
September 2005
February 2009   (final data collection date for primary outcome measure)
  • Fetal heart rate [ Time Frame: up to 300 minutes ] [ Designated as safety issue: No ]
  • Fetal movement [ Time Frame: up to 300 minutes ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00218621 on Archive Site
Neonatal abstinence syndrome [ Time Frame: 4 days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1
Maternal Buprenorphine Administration and Fetal/Infant Neurobehavior
The purpose of this study is to evaluate the effects of drugs used by treatment providers on the fetuses and infants of opiate dependent women. The subjects in this study are women enrolled in a large, multi-site, double blind study that looks at the effects of methadone and buprenorphine treatment during pregnancy. This study will evaluate fetal and maternal biophysiologic data longitudinally during pregnancy to determine how these substances may affect fetal neurobehavior. Additionally, infant neurobehavioral assessments and measurements of infant vagal tone will be collected to see how methadone and buprenorphine differentially affect the neonatal abstinence syndrome, or "withdrawal" in exposed neonates.
Previous research by this group has found that methadone treatment during pregnancy directly impacts fetal neurophysiology independently of maternal physiology. Buprenorphine is a new therapy for opiate dependent individuals, and its use during pregnancy is currently being evaluated. Some research has shown that buprenorphine lessens the neonatal abstinence syndrome when compared to methadone. Thirty methadone and 30 buprenorphine maintained women will be evaluated at 24, 28, 32 and 36 weeks gestation using a state-of-the-art computerized fetal actocardiograph and data analysis program to simultaneously evaluate fetal movement and heart rate and maternal physiologic parameters. Investigators will be blinded to treatment group. Longitudinal neurodevelopment of the fetuses in each group will be explored. The differential effects of methadone and buprenorphine on the neonatal abstinence syndrome will also be explored.
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Opioid dependent pregnant women enrolled in parent study (Maternal Opioid treatment: Human Experimental Research)
  • Opiate Dependence
  • Pregnancy
Procedure: Buprenorphine / methadone
Parallel study to double blind, double dummy study evaluating safety and efficacy of buprenorphine vs methadone treatment for pregnant opioid dependent women
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2009
February 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • generally healthy opiate dependent women
  • currently enrolled in the study "Maternal Opioid Treatment, Human Experimental Research study
  • uncomplicated singleton pregnancies

Exclusion Criteria:

  • complications of pregnancy, including HIV, diabetes, polyhydramnios, hypertension, preterm labor or placenta previa
  • evidence of fetal malformation
  • significant maternal health problems, including HIV infection
  • significant maternal psychopathology that would preclude informed consent, including schizophrenia
  • alcohol dependency per DSM IV criteria
18 Years to 40 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
04032202, R01DA019934, NIDA R01DA019934, DPMCDA
Not Provided
Not Provided
Lauren M. Jansson, Johns Hopkins University
Johns Hopkins University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Lauren M. Jansson, M.D. Johns Hopkins University
Johns Hopkins University
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP